63V Stock Overview
Develops prognostic and diagnostic tests for kidney transplant patients. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Verici Dx plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.038 |
| 52 Week High | UK£0.14 |
| 52 Week Low | UK£0.033 |
| Beta | 1.82 |
| 11 Month Change | 0% |
| 3 Month Change | -49.01% |
| 1 Year Change | -64.35% |
| 33 Year Change | -94.97% |
| 5 Year Change | n/a |
| Change since IPO | -92.65% |
Recent News & Updates
Recent updates
Shareholder Returns
| 63V | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 18.5% | -0.7% | -0.02% |
| 1Y | -64.4% | -17.2% | 8.2% |
Return vs Industry: 63V underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 63V underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 63V volatility | |
|---|---|
| 63V Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 63V's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 63V's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 19 | Sara Barrington | www.vericidx.com |
Verici Dx plc develops prognostic and diagnostic tests for kidney transplant patients. Its lead products are Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection. The company is also developing Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure.
Verici Dx plc Fundamentals Summary
| 63V fundamental statistics | |
|---|---|
| Market cap | €9.85m |
| Earnings (TTM) | -€4.62m |
| Revenue (TTM) | €4.16m |
2.4x
P/S Ratio-2.1x
P/E RatioIs 63V overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 63V income statement (TTM) | |
|---|---|
| Revenue | US$4.33m |
| Cost of Revenue | -US$3.00k |
| Gross Profit | US$4.34m |
| Other Expenses | US$9.15m |
| Earnings | -US$4.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.02 |
| Gross Margin | 100.07% |
| Net Profit Margin | -110.99% |
| Debt/Equity Ratio | 0% |
How did 63V perform over the long term?
See historical performance and comparison